Immunicon Corporation to Present at ISAC XXIII International Congress.HUNTINGDON VALLEY, Pa. -- Immunicon Corporation (NASDAQ-NM:IMMC IMMC Illinois Masonic Medical Center IMMC Integrated Materiel Management Center IMMC Intelligence Materiel Management Center IMMC Interdigestive Migrating Motor Complex IMMC International Meeting on Mine Clearance (UN) ) will present two oral presentations and three posters at the annual International Society for Analytical Cytology cytology (sītŏl`əjē), in biology, the study of the structure of all normal and abnormal components of cells and the changes, movements, and transformations of such components. (ISAC ISAC Illinois Student Assistance Commission ISAC Istituto di Scienze dell'Atmosfera e del Clima (Italy) ISAC International Society for Analytical Cytology ISAC Iowa State Association of Counties ISAC Information Sharing Analysis Center ) XXIII International Congress May 20-24 at the Quebec City Convention Center. In addition, collaborators from Twente University in the Netherlands will present four posters on Immunicon CellTracks(R) and EasyCount(TM) technologies. The presentations will address Immunicon's cellular analysis and molecular techniques for interrogating circulating cir·cu·late v. cir·cu·lat·ed, cir·cu·lat·ing, cir·cu·lates v.intr. 1. To move in or flow through a circle or circuit: blood circulating through the body. 2. tumor tumor: see neoplasm. cells for protein targets associated with cancer therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , chromosomal chromosomal, adj relating to chromosome, or a configuration within the cell's nucleus that contains a linear thread of DNA that conveys genetic data. chromosomal emanating from or pertaining to chromosome. abnormalities and over-expression of cancer-specific genes through fluorescent fluorescent having the quality of fluorescence. fluorescent antibody see fluorescence microscopy. fluorescent antibody test see fluorescence microscopy. in situ hybridization in situ hybridization A method for localizing a sequence of DNA, mRNA, or protein in a cell or tissue; the use of a DNA or RNA probe to detect a cDNA sequence in chromosome spreads or in interphase nuclei or an RNA sequence of cloned bacterial or cultured (FISH) testing, the next generation of Immunicon's CellTracks(R) technology, as well as the EasyCount(TM) System for rapid, accurate cell counting applications in the life science research market. Immunicon representatives will be available at Booth #409 to discuss their research.
Oral presentations will include:
-- Sunday, May 21, 2006
-- "Evaluation of Anti-Cancer Targets on Circulating Tumor
Cells to Predict Therapeutic Success," Dr. Leon
Terstappen, Chief Science Officer for Immunicon
Corporation, 9:15AM to 9:30AM, Abstract 150477, Room 304.
-- Monday, May 22, 2006
-- "Inherent Limitations in Rare Cell Detection," presented
by Arjan Tibbe, Branch Manager, Immunicon Europe, Inc.,
8:30AM to 8:45AM, Abstract 150262, Room 202.
Poster Presentations will include:
-- Monday, May 22, 2006
-- "Cell Orienting Microstructures for Image Cytometry"
presented by Tycho M. Scholtens, Twente University, 6:00PM
to 7:30PM, Abstract 149806; Poster P187, Room 400B/C.
-- "Point of Care Instrumentation For Affordable HIV
Monitoring" presented by Aurel Ymeti, Twente University,
6:00 PM to 7:30PM; Abstract 150001; Poster P189.
-- "Affordable Cell Enumeration for HIV Staging" will be
presented by Xiao Li, Twente University, 6:00PM to 7:30PM,
Abstract 150447; Poster P191.
-- "Assessment of Cell Viability with a Simple Imaging
Device" presented by Steven Gross, Immunicon, 6:00PM to
7:30PM, Astract 158088: Poster P199.
-- "Simple fluorescence-based image cytometer" presented by
Frank Coumans, Immunicon, 6:00PM to 7:30PM, Abstract
158354; Poster P201.
-- Tuesday, May 23, 2006
-- "A Fast Imaging Cytometer" presented by Frederik
Schreuder, Twente University, 6:00PM to 7:30PM, Abstract
149907; Poster P188.
-- "A Simple Fluorescence Imaging System to Enumerate
Residual Leukocytes in Leukodepleted Blood" presented by
Dania Yaskanin, Immunicon, 6:00PM to 7:30PM, Abstract
156053; Poster P198.
Following the conference, the Immunicon presentations will be posted on Immunicon's website at http://www.immunicon.com. For more about the ISAC XXIII International Congress, visit www.isac2006.com. About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells Endothelial cells The cells lining the inner walls of the blood vessels. Mentioned in: Von Willebrand Disease that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases infectious diseases: see communicable diseases. . www.immunicon.com. Forward-Looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. The information contained in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Immunicon's anticipated net cash burn for 2005, Immunicon's funding strategy for commercialization activities and key product and clinical development programs and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date of this press release, reflect management's current expectations and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by Immunicon's forward-looking statements. These factors include, but are not limited to, risks and uncertainties associated with: Immunicon's dependence on Veridex, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , a Johnson & Johnson company, in the field of cancer cell analysis; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of Immunicon's product candidates Immunicon's ability to use licensed products and to obtain new licenses from third parties; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. by third party payors to Immunicon's customers for Immunicon's products; compliance with applicable manufacturing standards; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; retaining key management or scientific personnel; delays in the development of new products or to planned improvements to Immunicon's products; effectiveness Immunicon's products compared to competitors' products; protection of Immunicon's intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission. "Immunicon" and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. "CellSpotter," "CellTracks" and "AutoPrep" are registered trademarks of Immunivest Corporation, a wholly-owned subsidiary of Immunicon Corporation. CellTracks Analyzer analyzer /ana·ly·zer/ (an´ah-li?zer) 1. a Nicol prism attached to a polarizing apparatus which extinguishes the ray of light polarized by the polarizer. 2. II is a trademark of Immunivest Corporation. "CellSearch" is a trademark of Johnson & Johnson. All other trademarks or servicemarks appearing in this report are the property of their respective holders. ALL RIGHTS RESERVED. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion